Physician profile
Michael Kruglet
NPI 1356656920
$1,965.80
in general payments reported to CMS, 2019-2025
12 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.88 · 2020: $18.00 · 2021: $248 · 2022: $344 · 2023: $534 · 2024: $396 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $445.62 | 2020-2025 | Clariti Contact Lens, Synergeyes Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $364.33 | 2021-2025 | Precision7, Precision 1, Dailies |
| Biotissue Holdings INC. | $251.94 | 2022-2024 | |
| Johnson & Johnson Vision Care, INC. | $224.58 | 2019-2025 | Acuvue |
| Rxsight INC | $148.75 | 2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $146.77 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $134.43 | 2022-2025 | Xiidra, Infuse, Alden Scleral Zenlens |
| Thea Pharma INC. | $67.27 | 2022-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $64.24 | 2024-2025 | Xdemvy |
| Abbvie INC. | $55.47 | 2022-2023 | |
| Amgen INC. | $47.88 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kruglet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.